Embryonal carcinoma (EC) cells, which are considered to be malignant counterparts of embryonic stem cells, comprise the pluripotent stem cell component of teratocarcinomas, a form of testicular germ cell tumors (GCTs). Nevertheless, many established human EC cell lines are nullipotent with limited or no capacity to differentiate under normal circumstances. In this study, we tested whether an over-expression of Yamanaka's reprogramming factors OCT4, SOX2, c-MYC and KLF4 might enable differentiation of the human nullipotent EC cells N2102Ep. Using OCT4 knockdown differentiated N2102Ep cells, we are able to derive reprogrammed N2102Ep cell lines. The induced pluripotency of N2102Ep allows the cells to differentiate toward neural lineage by retinoic acid; the expression of SSEA3 and SSEA4 is down-regulated, whereas that of neural surface markers is up-regulated. Consistent with the up-regulation of neural surface markers, the expression of the master neuroectodermal transcription factor PAX6 is also induced in reprogrammed N2102Ep. We next investigated whether PAX6 might induce spontaneous differentiation of nullipotent stem cells N2102Ep. However, while an ectopic expression of PAX6 promotes differentiation of NTERA2, it induces cell death in N2102Ep. We nevertheless find that upon induction of retinoic acid, the reprogrammed N2102Ep cells form mature neuronal morphology similar to differentiated pluripotent stem cells NTERA2 as determined by TUJ1 expression, which is absent in N2102Ep parental cells. Altogether, we conclude that the nullipotent state of human EC cells can be reprogrammed to acquire a more relaxed state of differentiation potential by Yamanaka's factors.
Introduction
Testicular germ cell tumors (GCTs) are the most common malignant cancer in young men between 20 and 40 years old [1, 2] . This pattern of the incidence occurring in young men is different from incidences of most cancers, which increase with age. One factor that might implicate the early onset of testicular GCTs is its embryonic cell origin from primordial germ cells (PGCs) which are recognized in human embryos at weeks 5-6. Seminoma and non-seminoma GCTs are the most predominant testicular GCTs. Seminoma is composed of cells that resemble PGCs, whereas non-seminoma testicular GCT may contain embryonal carcinoma (EC) cells together with elements of teratoma (together with EC cells, referred to as teratocarcinoma), yolk sac carcinoma and choriocarcinoma. The EC cells of teratocarcinoma are well recognized as pluripotent cancer stem cells capable of differentiating into somatic cells of all three embryonic germ layers [2] . Nevertheless, some GCTs are composed entirely of EC cells which have apparently lost their capacity for differentiation. Such apparently "nullipotent" EC cells may arise by mutation during cancer progression since a reduced capacity to differentiate would provide the cells with a selective growth advantage, leading to a more aggressive cancer phenotype [3] .
The mechanism by which nullipotent EC cells arise is unknown. Some mouse EC cell lines established in vitro are nullipotent [4] . Several studies in which such nullipotent mouse EC cells were fused to somatic cells resulted in hybrid cells with pluripotent characteristics, suggesting that nullipotency results from a mutation leading to the loss of function of gene(s) required for differentiation [5] [6] [7] [8] . A majority of human EC cell lines are nullipotent [9] [10] [11] [12] . For example, most human EC cell lines do not differentiate in response to retinoic acid [13] , which induces differentiation of mouse EC cells and the pluripotent human EC cell line NTERA2 [10] . Nevertheless, hybrids between a nullipotent human EC cell line N2102Ep and the pluripotent NTERA2 were capable of differentiation in response to retinoic acid, albeit without an ability to differentiate into mature neurons [14] . This finding suggests that the nullipotent state of human EC cells, like that of nullipotent mouse EC cells, results from the loss of some key differentiation inducers.
While the hybrid experiments point to mutations in the nullipotent EC cells limiting their capacity for differentiation, the nature of these mutations or the genes affected are unknown. Human embryonic stem (ES) cells in culture have been shown to acquire a variety of non-random genetic and epigenetic changes that also occur in human EC cells [15] [16] [17] . Hence, these genetic and/or epigenetic changes may arise because they confer similar selective advantages to such variant stem cells, whether in vitro or in vivo. In the case of N2102Ep human EC cells, which do not differentiate in response to retinoic acid, the cells nevertheless are capable of a response to retinoic acid since. For example, retinoic acid receptor beta (RARB) is induced in these cells by retinoic acid as it is in pluripotent NTERA2 EC cells [14, 18] . Therefore, the block of differentiation must be downstream of RARB. One possibility might be a failure to up-regulate the expression of key master developmental regulators such as PAX6, which has been shown to directly suppress the expression of stem cell-associated genes in human ES cells [19] , through genetic mutation of their regulatory or coding sequences. Another possibility is the genetic and/or epigenetic barrier within nullipotent EC cells, which does not allow the cells to differentiate. Such a barrier to differentiation has been suggested for mouse EC cells, which were unable to be reprogrammed by nuclear transfer [20] .
Despite their nullipotency, human EC cell lines such as N2102Ep express the characteristic surface antigen patterns that characterize both human pluripotent EC and ES cells [21] . They also have gene expression profiles similar to human ES cells, including similar expression levels of pluripotency-associated genes such as those used for the generation of human induced pluripotent stem (iPS) cells (e.g. OCT4, NANOG, SOX2, LIN28, and KLF4) [22] [23] [24] [25] . In the present study, we aimed to test whether the nullipotent stem cells N2102Ep could be induced to differentiate by reprogramming via Yamanaka's factors. We find that by reprogramming differentiated N2102Ep cells, which were generated by OCT4 knockdown, we are able to derive reprogrammed N2102Ep cell lines which show an ability to differentiate into neural lineage by induction of retinoic acid. Our study therefore suggests that the nullipotent state might be maintained in part by epigenetic mechanism(s), which suppress differentiation of nullipotent stem cells.
Materials and methods

Cell culture
Human EC cell lines N2102Ep [26] and NTERA2 [9] were grown in DMEM with 10% FBS (Invitrogen), and placed at 37°C under a humidified atmosphere of 10% CO 2 incubator. N2102Ep and NTERA2 were passaged every 3 days using 0.25% and 0.05% trypsin, respectively. Reprogrammed N2102Ep cell lines RepN5 and RepN13, which were generated by iPS reprogramming (see below), were cultured in human ES culture condition, i.e. Knockout-DMEM supplemented with 20% Knockout-Serum Replacement, 1× non-essential amino acids, 1 mM glutamine, 0.1 mM beta-mercaptoethanol and 4 ng/ml bFGF (Invitrogen) seeded on 6 × 10 3 cells/cm 2 mitomycin C-treated MF-1 mouse embryonic fibroblasts (MEFs), and placed at 37°C under a humidified atmosphere of 5% CO 2 incubator. Cells were passaged every 5-7 days using collagenase type IV (Invitrogen) and scraping with glass-beads (Sigma). NTERA2 and parental N2102Ep harboring OCT4 inducible shRNAi system (see below) were cultured under this human ES condition for differentiation study. To induce differentiation, the culture medium was supplemented with 10 μM of all-trans retinoic acid (Sigma).
Generation of differentiated N2102Ep by OCT4 knockdown and induced pluripotency
N2102Ep cell line harboring tetracycline repressor (TetR) and short hairpin interfering RNA targeting OCT4 was established by transfecting pCAG-TetRnls-IRES-puromycin and pSuperior-Neo (Oligoengine) containing OCT4 siRNA [27] . Principally, inside the cells the plasmid pCAG-TetRnls-IRES-puromycin constitutively encodes the tetracycline repressor TetR, which will in turn bind to the shRNA promoter region of the plasmid pSuperior-Neo in the absence of doxycycline, thereby suppressing shRNA expression. In the presence of doxycycline, which is a ligand of TetR, the repressor is then evicted from the shRNA promoter leading to an expression of shRNA [27] . Stable transfected N2102Ep colonies were selected and expanded using 3 μg/ml puromycin and 750 μg/ml G418 (Invitrogen). Reverse transcription quantitative polymerase chain reaction and western blotting were employed to validate the expression of OCT4 knockdown in cells grown with or without 1 μg/ml doxycycline.
To generate iPS cells, N2102Ep OCT4 knockdown cells were treated with 1 μg/ml doxycycline for two weeks to derive differentiated cells. The medium was changed every 3 days. The expression of SSEA3 and SSEA1 and the cloning efficiency test were performed to assure a complete differentiation of N2102Ep. Differentiated OCT4 knockdown cells were then transfected by PmeI-linearized four-in-one plasmid over-expressing OCT4, SOX2, c-MYC and KLF4 jointly expressed by 2A peptides together with puromycin resistant gene and a red fluorescence protein (RFP) (Supplementary Fig. 1 ). Transfected cells were immediately transferred to human ES culture condition. Colonies stably expressing the reprogramming factors, as indicated by RFP-positive expression, were manually selected [28] . Two reprogrammed N2102Ep (RepN) clones were subsequently tested for their differentiation potential, i.e. clones RepN5 and RepN13. The expression of SSEA3 and SSEA4 was confirmed in the reprogrammed N2102Ep cell lines by the flow cytometry analysis. The expression of stem cell-associated genes OCT4 and NANOG was confirmed by qPCR.
Establishment of PAX6 over-expressing N2102Ep and NTERA2 cell lines
The human PAX6 coding sequence was amplified from a plasmid containing PAX6 gene (kindly provided by Prof. Su-Chun Zhang, University of Wisconsin, Madison). A FLAG tag-containing primer was used to add the peptide at the 5′-position of the coding sequence to allow detection of the transgene by anti-FLAG antibody (Sigma). The FLAG-PAX6 DNA fragment was gel-purified using a DNA extraction kit from Qiagen. A red fluorescence protein (RFP) encoding gene of pCAG-RFP-IRESpuromycin was excised using XhoI and NotI, and was replaced by the FLAG-PAX6 DNA fragment. The plasmid pCAG-FLAG-PAX6-IRESpuromycin was then transfected into either N2102Ep or NTERA2 to establish the PAX6 over-expressing cell lines using electroporation. Briefly, human EC cells were dissociated using 0.25% trypsin. One million cells were then transfected with 3 μg of PvuI-linearized plasmid DNA. pCAG-RFP-IRES-puromycin was also separately transfected in the parental N2102Ep and NTERA2 to establish control cell lines. The transfectants were immediately plated in DMEM-F12 plus 10% FBS (Invitrogen). Three days after the transfection, 3 μg/ml puromycin (Sigma) was added to the culture medium to select colonies which were resistant to the antibiotic. Western blotting was employed to test PAX6 overexpression in the human EC cell lines.
Western blotting
Cell pellets were resuspended in RIPA buffer (150 mM NaCl, 1% (w/v) sodium deoxycholate, 25 mM Tris-Cl pH 8.0, 1% (v/v) NP-40, and 0.1% (w/v) SDS, protease inhibitor cocktails), and were subjected to sonification. Protein concentration was determined using a bicinchoninic acid (BCA) protein assay kit (Thermo Scientific). Forty micrograms of proteins was loaded in each well. Proteins were transferred to PVDF membrane (Invitrogen). Antibodies for western blotting are as followed; Rabbit polyclonal antibody against PAX6 (PA1-801) from Thermo Scientific; mouse monoclonal antibody against OCT4 (sc-101534) from Santa Cruz; mouse monoclonal antibody against ACTB (A5316) from Sigma.
Reverse transcription quantitative polymerase chain reaction (RT-qPCR)
RNA was extracted using TRIzol reagent (Invitrogen), and was DNase-treated using TURBO DNA-free (Ambion). Complementary DNA synthesis was performed with 1 μg RNA. qPCR was carried on by using SYBR Green JumpStart Taq ReadyMix (Sigma) in a total volume of 20 μl each well with an iCycler iQ system (Biorad). Gene expression was normalized by the expression level of ACTB. Primer sequences are available upon request.
Cloning efficiency assay
Cells were washed once with PBS, and were disaggregated to single-cell level using 0.25% trypsin. Cells were seeded at 500 cells with DMEM-F12 with 10% FBS, in a six-well plate. After a twoweek culture, cells were washed once with PBS and ice-cold methanol, respectively. Cells were fixed with 1 ml of the methanol for 15 min at room temperature. The methanol was removed, and cells were incubated with 1 ml of a crystal violet solution (0.4% (w/v) in methanol) for another 15 min. Unstained crystal violet was washed off by water. The plates were dried and were counted for colony numbers.
Flow cytometry
Flow cytometry was performed as previously described [21] . Briefly, cultured cells were harvested by trypsinization. One hundred thousand cells in 100 μl PBS with 10% FCS were incubated with primary monoclonal antibodies including P3X (negative control), SSEA3, SSEA4, A2B5, B159, Vinis56 and Vin2Pb22 at 1:10 dilution for 30 min. Cells were washed and incubated with FITC-conjugated secondary antibody (Jackson Laboratory). Cell surface expression was then analyzed by a Cyan bench-top flow cytometer (Dako Cytomation).
Immunofluorescence staining
N2102Ep, NTERA2 and reprogrammed N2102Ep cells were grown in a 24-well chamber with retinoic acid induction for three weeks, and were fixed with 4% PFA. Fixed cells were permeabilized with 0.5% Triton-X 100, and were incubated with monoclonal rabbit anti-TUJ1 (MRB-435P, Covance). A secondary antibody conjugated with FITC (Santa Cruz) was then used for visualization under an InCell Analyzer fluorescence microscope workstation system (GE Healthcare).
Results
Ectopic expression of reprogramming factors induces cell death in nullipotent N2102Ep EC cells
We first asked whether the nullipotent state can be destabilized by an ectopic expression of Yamanaka's factors OCT4, SOX2, c-MYC and KLF4, to acquire differentiation potential in N2102Ep, albeit already expressing high expression levels of the genes similar to pluripotent stem cells [22, 23] . A single plasmid driving expression of the four factors under CAG promoter ( Supplementary Fig. 1A ), was transfected into N2102Ep. With the use of an internal ribosome entry site (IRES), a puromycin resistant gene and a gene encoding RFP are also transcribed under the same CAG promoter together with the four factors [28] . We found that, however, RFP-positive cells failed to proliferate, and could not survive eventually after puromycin selection ( Supplementary  Fig. 1B) . On the other hand, a selection of puromycin resistant colonies of N2102Ep transfected with pCAG vector encoding only puromycin resistant gene and RFP, but not the reprogramming factors, yielded stable N2102Ep cell line expressing RFP (Fig. 5B, see below) . In addition, transfection of the reprogramming plasmid into the pluripotent NTERA2 cells enabled puromycin selection of proliferating RFPpositive cells (Supplementary Fig. 1B) . These results indicate that over-expression of the reprogramming factors is highly toxic to N2102Ep but not to NTERA2.
Reprogramming of nullipotent N2102Ep EC cells by induced pluripotency
The failure to establish undifferentiated nullipotent stem cells N2102Ep over-expressing the reprogramming factors might be due to genetic and/or epigenetic incompatibility of the stem cells to respond to the transgene expression. We have previously reported that silencing of OCT4 by transient siRNA leads to differentiation of N2102Ep at high efficiency [29] . To ascertain whether differentiated N2102Ep cells are permissive for reprogramming, we induced differentiation of N2102Ep nullipotent stem cells with an inducible shRNA (shRNAi) system to knockdown OCT4 upon doxycycline treatment [27] . Treatment of OCT4 knockdown N2102Ep cells with doxycycline led to down-regulation of OCT4 as determined by qPCR and western blot analysis (Fig. 1A-B) . Morphological examination of OCT4 knockdown N2102Ep cells revealed a differentiated phenotype of doxycycline-treated culture (Fig. 1C) . In addition, silencing of OCT4 led to a loss of SSEA3 and a gain of SSEA1 representing human pluripotent stem cell and differentiation markers, respectively (Fig. 1D) . Moreover, OCT4 knockdown completely abolished the appearance of stem cell colonies (Fig. 1E) . These results therefore indicate an efficient and massive differentiation of nullipotent N2102Ep cells by inducible silencing of OCT4.
We next determined whether iPS reprogramming of OCT4 knockdown differentiated N2102Ep would yield stem cells with an ability of differentiation similar to pluripotent stem cells. To this end, OCT4 expression was depleted by repeated treatment with doxycycline for more than two weeks to ensure loss of undifferentiated stem cells (Fig. 1C-E) . The differentiated N2102Ep cells were transfected by the reprogramming plasmid, and were directly seeded on MEFs with human ES medium. RFP-positive colonies were observed approximately 2 weeks after seeding ( Fig. 2A) , which were then picked at day 30 to expand RFP-positive cells. These reprogrammed N2102Ep cell lines possess similar morphology to human ES cells and express SSEA3, SSEA4, OCT4 and NANOG (Figs. 3 and 4 and Supplementary Figs. S3 and S4) , which are markers of human ES cells [30] . Specifically, the reprogrammed N2102Ep cells express SSEA3 at 60-70% and SSEA4 at 90-95% of total population; the former has been shown to be the most sensitive marker of human ES cell state [21] . In addition, similar to their parental cells, they were able to differentiate following exposure to doxycycline (Fig. 2B ).
Induced pluripotency enables neural differentiation of reprogrammed nullipotent N2102Ep EC cells
To elucidate whether reprogrammed N2102Ep cells had gained a capability of differentiation in response to retinoic acid similar to their pluripotent counterpart NTERA2, the cells were tested for surface marker and gene expression in response to retinoic acid treatment. In N2102Ep parental control cells, retinoic acid treatment caused no significant change of expression of surface markers confirming that they do not differentiate in response to retinoic acid exposure ( Fig. 3 and Supplementary Fig. 2) . In contrast to their parental N2102Ep control cells, two reprogrammed N2102Ep cell lines, RepN5 and RepN13, expressed a lower level of SSEA3 and SSEA4. Further, retinoic acid treatment resulted in marked down-regulation of these stem cell markers ( Fig. 3 and Supplementary Figs. 3-4) . Also, approximately 10-20% of cells expressing neural differentiation markers A2B5, B159, VINIS56 and VIN2Pb22 were observed in RepN5 and RepN13 on day 21 of retinoic acid treatment ( Fig. 3 and Supplementary Figs. 3-4) . By comparison, in NTERA2 more than 50% of cells expressing those markers were observed as soon as day 7 of retinoic acid treatment ( Fig. 3 and Supplementary Fig. 5 ). This result suggests that the reprogrammed N2102Ep cell lines RepN5 and RepN13, unlike their parental N2102Ep, differentiate into neural lineage in response to retinoic acid, albeit with a slower effect and a lower degree of differentiation compared with NTERA2.
We next asked whether retinoic acid treatment would downregulate the expression of stem cell-associated genes as well as upregulate differentiation-associated genes in RepN5 and RepN13. The result shows that, consistent with the flow cytometry data, the expression of OCT4 and NANOG was not down-regulated by retinoic acid induction in N2102Ep control (Fig. 4) . Moreover, differentiationassociated genes PAX6, NEUROD1 and HOXB9 were not up-regulated in the control parental cells. However, GATA6 showed an induction about 5-fold approximately in N2102Ep treated with retinoic acid. Among genes encoding retinoic acid receptors, we found that the expression level of retinoic acid receptor beta (RARB) was induced by retinoic acid treatment in N2102Ep (Supplementary Fig. S6 ), supporting our previous finding [14] . However, the expression level of RARA and RARG was not altered by retinoic acid treatment. Thus, in the absence of a down-regulation of stem cell-associated genes and an unperturbed expression of stem cell surface markers, these results indicate that the nullipotent stem cells N2102Ep fail to undergo differentiation in response to retinoic acid.
In RepN5, RepN13 and NTERA2, where the expression level of cell surface markers associated with the stem cell state was reduced in response to retinoic acid (Fig. 3) , the expression of OCT4 was also down-regulated by retinoic acid treatment (Fig. 4) . However, in contrast to NTERA2, the expression of NANOG was not decreased in RepN5 and RepN13 by retinoic acid treatment. Similar to the parental nullipotent N2102Ep, the expression level of RARB but not RARA or RARG was induced by retinoic acid in RepN5, RepN13 and NTERA2 (Supplementary Fig. S6) . Interestingly, the expression of differentiationassociated genes PAX6 and NEUROD1 (neural differentiation), HOXB9 (mesodermal differentiation) and GATA6 (endodermal differentiation) was also up-regulated in RepN5, RepN13 and NTERA2. Therefore, consistent with the surface marker expression, these results suggest that the reprogrammed N2102Ep cells undergo differentiation in response to retinoic acid, particularly into neural lineage as determined by the expression of A2B5, B159, VINIS56, VIN2Pb22, PAX6 and NEUROD1.
Differential response of PAX6 over-expression in nullipotent N2102Ep and pluripotent NTERA2 EC cells
Since the reprogrammed N2102Ep cell lines, but not their parental control cells, can be induced to differentiate into neural lineage based on surface marker and gene expression (Figs. 3 and 4) , we asked whether a simple over-expression of PAX6 might induce neural differentiation of wild-type N2102Ep nullipotent stem cells. We chose to test the role of PAX6 in neural differentiation induction because (1) we detected an upregulation of neural surface markers, (2) PAX6 is induced in reprogrammed N2102Ep cells by retinoic acid, and (3) an over-expression of PAX6 has been shown to spontaneously and efficiently induce differentiation of human ES cells [19] . In contrast to PAX6, the role of NEUROD1, HOXB9 or GATA6 in spontaneous differentiation of human ES cells has never been reported.
We transfected a plasmid containing PAX6 coding sequence under CAG promoter or a control parental plasmid (CAG-RFP) into nullipotent and pluripotent EC cells N2102Ep and NTERA2, respectively. Western blot analysis of FLAG tag revealed the expression of the ectopic PAX6 over-expression in the two cell lines (Fig. 5A) . However, upon longtermed selection of puromycin, N2102Ep cells over-expressing PAX6 were completely detached from culture. On the other hand, we were able to establish NTERA2 cell lines over-expressing PAX6 (Fig. 5B) . This result indicates that PAX6 might be very toxic to N2102Ep. Flow cytometry analysis of NTERA2 over-expressing PAX6 shows that the PAX6 transgene down-regulates the expression of the stem cell marker SSEA3, whereas that of the neural differentiation marker Fig. 3 . Retinoic acid induces expression of cell surface markers characteristic of neural differentiation in reprogrammed N2102Ep. Cells were induced to differentiate by 10 μM retinoic acid for a period of three weeks. Expression of surface markers was determined by flow cytometry. Expression of all surface markers including the stem cell-associated SSEA3 and SSEA4, and neural differentiation-associated A2B5, B159, Vinis56 and Vin2PB22, is not altered upon retinoic acid induction of N2102Ep. In contrast, RepN5, RepN13 and NTERA2 down-regulate expression of SSEA3 and SSEA4, whereas that of A2B5, B159, Vinis56 and Vin2Pb22 is up-regulated by retinoic acid. Data are shown as mean ± SD; n = 3. * p b 0.05.
A2B5 is up-regulated (Fig. 5C) . Furthermore, RT-PCR analysis shows that PAX6 over-expression up-regulates the expression of neural specific genes (Fig. 5D ) supporting the role of PAX6 in neural induction of human pluripotent stem cells [19] . These results thus indicate that an over-expression of PAX6 is not compatible with survival of wild-type N2102Ep, but induces differentiation of the pluripotent stem cells NTERA2.
Differentiation of reprogrammed N2102Ep into mature neurons
The hybrid cell line C10 established from NTERA2 and N2102Ep has been shown to be incapable of the generation of mature neurons [14] . Since surface markers involved in neural differentiation, i.e. A2B5, B159, VINIS56 and VIN2Pb22 (Fig. 3) as well as genes involved in neural differentiation (Fig. 4) were induced in RepN5 and RepN13 by retinoic acid treatment, an immunostaining was performed using TUJ1 antibody to test whether mature neurons would be induced by retinoic acid from the reprogrammed RepN5 and RepN13 cells. The result shows that RepN5 and RepN13 generated from iPS reprogramming produced TUJ1-positive cells indicating the presence of mature neurons upon retinoic acid treatment (Fig. 6 ). This neuronal differentiation was not seen in the control N2102Ep. Altogether, these results suggest that RepN5 and RepN13 are able to be induced to differentiate into mature neurons similar to those of NTERA2 in vitro, and that the iPS reprogramming can alter the nullipotent state of N2102Ep into a more relaxed stem cell state with a capability of differentiation.
Discussion
Although the molecular and cellular biology of human EC cells has been studied for more than three decades, the mechanism(s) behind nullipotency, an operational definition used to describe stem cells that appear to have lost the capacity to differentiate, has been elusive. By using cell fusion techniques, several independent observers have proposed that the nullipotency is conferred by genetic mutation of a gene(s) involved in differentiation, leading to the attenuation of EC cells to differentiate [5] [6] [7] [8] 14] .
To further examine whether the failure of N2102Ep EC cells to differentiate could be due to epigenetic suppression of other critical regulatory genes, we attempted to over-express the set of Yamanaka's factors, i.e. OCT4, SOX2, c-MYC and KLF4, used for reprogramming somatic cells to a pluripotent state. However, direct transfection of the plasmid encoding these four factors into undifferentiated nullipotent stem cells N2102Ep failed to establish a stable cell line, although we were able to generate NTERA2 EC cells over-expressing these reprogramming factors ( Supplementary Fig. 1 ). Nevertheless, after N2102Ep EC cells were induced to differentiate by knocking down the expression of OCT4 by an inducible shRNA system, we found that the resulting differentiated cells could be reprogrammed back to an undifferentiated, EC-cell like state by over-expression of the four factors.
Down-regulation of SSEA3, SSEA4 and OCT4 and up-regulation of A2B5, B159, VINIS56, VIN2Pb22, PAX6 and NEUROD1 upon retinoic acid induction suggest that the reprogrammed N2102Ep, unlike their parental cells, possesses an ability to differentiate into neural lineage (Figs. 3-4) . Moreover, in contrast to the N2102Ep-NTERA2 hybrid experiment which failed to yield TUJ1-positive cells [14] , the reprogramming by Yamanaka's factors resulted in the generation of TUJ1-positive cells from the reprogrammed N2102Ep (Fig. 6) . Although the parental N2102Ep cells maintain high expression levels of SSEA3, SSEA4 and OCT4 similar to the reprogrammed N2102Ep cells when cultured under human ES cell culture condition (Figs. 3-4) , unlike their reprogrammed counterparts they do not differentiate by retinoic acid treatment. These results suggest that the culture condition alone, without iPS reprogramming, is not sufficient to allow the parental N2102Ep cells to differentiate. Together, these results suggest that epigenetic changes might play an important role for the nullipotency of N2102Ep cells during tumor evolution and progression.
Retinoic acid receptor gamma (RARG) has been reported to play a major role in differentiation of NTERA2 and its retinoic acid resistant subclones [31] [32] [33] . We have previously shown that the hybrid cell line C10, which was generated by fusion between NTERA2 and N2102Ep, expresses RARG and RARB at similar levels compared to its parental cell lines, and that expression level of RARB is also induced by retinoic acid in NTERA2, N2102Ep and C10 [14] . We found that the expression pattern of RARA, RARB, RARG is similar between the reprogrammed N2102Ep cell lines RepN5 and RepN13 and their parental nullipotent N2102Ep cells (Supplementary Fig. 6 ). Therefore, the differentiation potential of the reprogrammed N2102Ep might be independent of pathways involving retinoic acid receptors.
Several studies have suggested that iPS cells might retain a certain degree of epigenetic memory similar to somatic cells from which they are derived from [34] [35] [36] [37] . This retention of epigenetic memory might involve histone modification [36] and DNA methylation [37] . It might be possible that a germline-specific epigenetic memory might still persist in wild-type nullipotent N2102Ep cells [38] , and that the germline memory might be erased in OCT4-knockdown differentiated cells. Therefore, the differentiated N2102Ep cells are now compatible with iPS reprogramming, which allows the differentiated cells to be reprogrammed into cells more similar to pluripotent EC cells than to nullipotent EC cells.
EC and ES cells have been shown to possess different epigenetic profiles. A novel assay namely nucleosome enzyme-linked immunosorbent assay (NU-ELISA) has been developed to quantify global levels of histone modifications in ES and EC cells [39] . The study has shown that mouse EC cells contain level of H3K4me1 at 10-fold less than mouse ES cells, whereas levels of H3K9me1, H3K9me3 and H3K79me2 are higher in EC cells than ES cells. By comparing genome-wide occupancy of H3K4me3 and H3K27me3, Robertson and colleagues have revealed differences in occupancy of the two histone marks between human ES and EC cells, particularly at bivalent domains [40] . The authors also utilized methyl CpG-binding domain protein-high throughput sequencing (MBD-seq) to compare enrichment of MBD, which represents the presence of DNA methylation, in human ES and EC cells. Interestingly, the analysis shows that the patterns of MBD binding are remarkably different in the two cell types. Moreover, human ES cells possess higher levels of MBD binding at gene body than human EC cells [40] . The discrepancy of DNA methylation profiles in human ES and EC cells might be due to a germline-like state of EC cells, which has undergone global DNA demethylation [41] [42] [43] [44] . To support this notion, biallelic Gene expression analysis was performed by RT-qPCR using stem cell-and neural-associated genes in NTERA2 over-expressing PAX6. Note that primers for PAX6 are specific to its 3′UTR of endogenous but not ectopic PAX6 transcript. Data are shown as mean ± SD; n = 3. expression of imprinted genes has been shown to be a general feature of NTERA2 compared with human ES cells [45] , although global DNA methylation profiles of NTERA2 and human ES cells closely resemble each other [46] .
In conclusion, our study indicates that nullipotent EC cells can be reprogrammed to acquire an ability to differentiate by Yamanaka's factors. Since nullipotent EC cells have been suggested as the cancer stem cells with a strong genetic influence, this finding suggests that the nullipotent state might be maintained not only by the genetic influence, but also by other abnormalities such as an epigenetic instability.
Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.bbamcr.2014.07.013.
